B O O K - American College of Rheumatology

7:30 PM
Role of IL-1 in Human Articular Cartilage: Lessons from
Osteoarthritis
Dirk Elewaut, MD, PhD; Universitair Ziekenhuis Gent; Ghent,
Belgium
7:45 PM
Anakinra for the Treatment of Macrophage Activation
Syndrome
Randy Q. Cron, MD, PhD; Children’s Hospital of Alabama;
Birmingham, AL
Session Overview:
The ACR/EULAR Academic Exchange Program seeks to bring
together young academic rheumatologists from Europe and
the United States to discuss basic and translational research
programs in order to foster exchange of ideas and collaboration.
The annual meeting of the ACR is an ideal forum in which to
promote and encourage this kind of interaction. This particular
session aims to highlight the new developments on the role
of inflammatory diseases. This will be the 11th year of the
study group meeting at the ACR Annual Scientific Meeting. Last
year was highly successful with invited speakers, Drs. Thomas
Huizinga and Robert Winchester, as well as two speakers from
within the exchange group. The attendance was high and it was
a great opportunity for interactions and exchanges between
researchers from both sides of the Atlantic. This year’s session
promises to be equally stimulating and productive.
Upon completion of this session, participants should be able to:
• identify new developments in the treatment of
autoinflammatory diseases
• identify novel molecular mechanisms of IL-1 signaling
pathways in inflammatory diseases
Session Overview:
The antiphospholipid syndrome is a rapid evolving field of high
interest to rheumatologists. The disease affects a significant
proportion of SLE patients. APS is associated with thrombosis,
pregnancy losses and aPL antibody positivity. A significant
number of questions particularly with respect to treatment and
diagnostic tests remain unanswered that will be discussed in
this study group by internationally and well-recognized scientists
in the field. Importantly new findings on pathogenesis of the
disease may lead to the development of novel therapies to treat
clinical manifestations of APS.
Upon completion of this session, participants should be able to:
• discuss new pathogenic mechanisms of thrombosis in APS
• describe new targeted therapies to be used in treatment of
APS
• discuss updates on antiphospholipid testing used in diagnosis
of APS
• describe clinical trials and studies in APS
A411
Autoantibodies in Diagnosis and Follow Up of
Rheumatic Diseases
Moderator: Pierluigi Meroni, MD; Instituto G. Pini University;
Milano, Italy
6:45 PM
Opening Comments
Pierluigi Meroni, MD; Instituto G. Pini University; Milano, Italy
6:50 PM
Clinical Use of Anti-Citrullinated Peptide Antibodies for Setting
a Phenotypic Diagnosis of RA
Solbritt M. Rantapaa-Dahlqvist, MD, PhD; Umea, Sweden
tuesday
A314
Antiphospholipid Syndrome
Moderator: Silvia S. Pierangeli, PhD; University of Texas Medical
Branch; Galveston, TX
6:45 PM
Pathogenic Mechanisms in APS - Can They Lead us to New
Therapies?
Anisur Rahman, MD; University College London; London, United
Kingdom
7:00 PM
A New Mechanism in the Pathogenesis of the Antiphospholipid
Syndrome: Implications for Thrombotic Risks Ratification
Steven Krillis, MD; The University of New South Wales; Syndey,
Kogarah, NSW, Australia
7:15 PM
Antiphospholipid Antibodies: Diagnostic Strategies for the
Clinical Laboratory
Tom Ortel, MD; Duke University Health System; Durham, NC
7:30 PM
The PROMISSE Study
Jane E. Salmon, MD; Hospital for Special Surgery; New York, NY
7:45 PM
The APLA 2010 Congress: Update on Wet Workshop and APL
Testing Task Force Recommendations
E. Nigel Harris, MD; The University of the West Ind; Kingston,
Jamaica
7:15 PM
Autoantibodies as Diagnostic and Prognostic Markers in Early
Arthritis
Gunter Steiner, PhD; Medical University of Vienna; Vienna,
Austria
7:35 PM
Update on Inaccurate ANA in Southeast
Merlin R. Wilson, MD; Wilson & Sanders Inc. Group Lab; New
Orleans, LA
7:45 PM
FDA Update on ANA Testing
Marilyn Lightfoote, PhD; Food and Drug Administration; Silver
Spring, MD
Session Overview:
This is the fifth year that the Autoantibody Standardization
Committee has organized this study group. For the 2007
meeting we had 250 participants; for 2008 and 2009, we had
400 participants. The goal of our committee is to promote
the accurate use of autoantibodies with a clear focus on the
relevance to practicing clinicians and clinical laboratories. There
is a continuing need for rheumatologists to keep up-to-date with
the rapidly progressing field of autoantibody diagnostics and
their relevance to the diagnosis and management of rheumatic
diseases.
2010 Program Book 87